Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Schizophrenia

  Free Subscription


Articles published in Neuropsychopharmacology

Retrieve available abstracts of 58 articles:
HTML format
Text format



Single Articles


    May 2018
  1. HOLPER L, Ben-Shachar D, Mann JJ
    Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.
    Neuropsychopharmacology. 2018 May 16. pii: 10.1038/s41386-018-0090.
    PubMed     Text format     Abstract available


  2. NOUR MM, McCutcheon R, Howes OD
    The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis.
    Neuropsychopharmacology. 2018;43:1195-1196.
    PubMed     Text format    


    April 2018
  3. NEVES GA, Grace AA
    alpha7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia.
    Neuropsychopharmacology. 2018 Apr 19. pii: 10.1038/s41386-018-0066.
    PubMed     Text format     Abstract available


  4. CHIAPPELLI J, Rowland LM, Notarangelo FM, Wijtenburg SA, et al
    Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 18. pii: 10.1038/s41386-018-0072.
    PubMed     Text format     Abstract available


  5. HAFIZI S, Da Silva T, Meyer JH, Kiang M, et al
    Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study.
    Neuropsychopharmacology. 2018 Apr 13. pii: 10.1038/s41386-018-0061.
    PubMed     Text format     Abstract available


  6. AVRAM M, Brandl F, Bauml J, Sorg C, et al
    Cortico-thalamic hypo- and hyperconnectivity extend consistently to basal ganglia in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 12. pii: 10.1038/s41386-018-0059.
    PubMed     Text format     Abstract available


  7. ERMAKOVA AO, Knolle F, Justicia A, Bullmore ET, et al
    Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis.
    Neuropsychopharmacology. 2018 Apr 5. pii: 10.1038/s41386-018-0056.
    PubMed     Text format     Abstract available


    March 2018
  8. DOGAN AE, Yuksel C, Du F, Chouinard VA, et al
    Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.
    Neuropsychopharmacology. 2018 Mar 14. pii: 10.1038/s41386-018-0041.
    PubMed     Text format     Abstract available


    February 2018
  9. CHIAPPELLI J, Notarangelo FM, Pocivavsek A, Thomas MAR, et al
    Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 27. pii: 10.1038/s41386-018-0038.
    PubMed     Text format     Abstract available


  10. O'DONOVAN SM, Sullivan C, Koene R, Devine E, et al
    Cell-subtype-specific changes in adenosine pathways in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 26. pii: 10.1038/s41386-018-0028.
    PubMed     Text format     Abstract available


  11. BARNETT I, Torous J, Staples P, Sandoval L, et al
    Relapse prediction in schizophrenia through digital phenotyping: a pilot study.
    Neuropsychopharmacology. 2018 Feb 22. pii: 10.1038/s41386-018-0030.
    PubMed     Text format     Abstract available


  12. BERNSTEIN HG, Dobrowolny H, Keilhoff G, Bogerts B, et al
    Reduced Density of DISC1 Expressing Astrocytes in the Dentate Gyrus but not in the Subventricular Zone in Schizophrenia.
    Neuropsychopharmacology. 2018;43:457-458.
    PubMed     Text format    


    January 2018
  13. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Jan 30. pii: 10.1038/s41386-017-0004.
    PubMed     Text format     Abstract available


  14. YOUNG JW, Light GA
    Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap.
    Neuropsychopharmacology. 2018;43:230-231.
    PubMed     Text format    


    December 2017
  15. DOYLE GA, Berrettini WH
    Failure to Replicate an Association of a LINE-1 Element in ERI1 Exoribonuclease Family Member 3 (ERI3) with Schizophrenia.
    Neuropsychopharmacology. 2017;42:2471.
    PubMed     Text format    


    November 2017
  16. PERKINS KA, Chengappa KR, Karelitz JL, Boldry MC, et al
    Initial Cross-Over Test of a Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers with or Without Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 29. pii: npp2017292. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  17. SWERDLOW NR, Bhakta SG, Talledo JA, Franz DM, et al
    Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.
    Neuropsychopharmacology. 2017 Nov 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  18. NAGELS A, Cabanis M, Oppel A, Kirner-Veselinovic A, et al
    S-Ketamine-Induced NMDA Receptor Blockade During Natural Speech Production and its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  19. STEFANIK L, Erdman L, Ameis SH, Foussias G, et al
    Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  20. GIRGIS RR, Ciarleglio A, Choo T, Haynes G, et al
    A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 1. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    September 2017
  21. SMUCNY J, Lesh TA, Newton K, Niendam T, et al
    Levels of Cognitive Control: A Functional Magnetic Resonance Imaging-Based Test of an RDoC Domain Across Bipolar Disorder and Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  22. RAMSAY IS, Fryer S, Boos A, Roach BJ, et al
    Response to Targeted Cognitive Training Correlates with Change in Thalamic Volume in a Randomized Trial for Early Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    August 2017
  23. KEM WR, Olincy A, Johnson L, Harris J, et al
    Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.
    Neuropsychopharmacology. 2017 Aug 21. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  24. O'DONNELL P
    Microglia Activation in Subjects at Risk for Psychosis, Fact or Fiction?
    Neuropsychopharmacology. 2017 Aug 18. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  25. LEE M, Balla A, Sershen H, Sehatpour P, et al
    Rodent Mismatch Negativity (MMN)/Theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Neuropsychopharmacology. 2017 Aug 17. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    July 2017
  26. BRUCATO G, Appelbaum PS, Lieberman JA, Wall MM, et al
    A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort.
    Neuropsychopharmacology. 2017 Jul 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    June 2017
  27. COSGROVE D, Mothersill O, Kendall K, Konte B, et al
    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory.
    Neuropsychopharmacology. 2017 Jun 13. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  28. HAFIZI S, Da Silva T, Gerritsen C, Kiang M, et al
    Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: An In-Vivo PET Study with [18F]FEPPA.
    Neuropsychopharmacology. 2017 Jun 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  29. DOYLE GA, Crist RC, Karatas ET, Hammond MJ, et al
    Analysis of LINE-1 Elements in DNA from Postmortem Brains of Individuals with Schizophrenia.
    Neuropsychopharmacology. 2017 Jun 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    April 2017
  30. RABIN RA, Barr MS, Goodman MS, Herman Y, et al
    Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls.
    Neuropsychopharmacology. 2017 Apr 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  31. LIGHT GA, Zhang W, Joshi YB, Bhakta S, et al
    Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology. 2017 Apr 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  32. EISENBERG DP, Yankowitz L, Ianni AM, Rubinstein DY, et al
    Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.
    Neuropsychopharmacology. 2017 Apr 7. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    March 2017
  33. SARPAL DK, Robinson DG, Fales C, Lencz T, et al
    Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia.
    Neuropsychopharmacology. 2017 Mar 15. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  34. POGORELOV VM, Rodriguiz RM, Cheng J, Huang M, et al
    5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.
    Neuropsychopharmacology. 2017 Mar 15. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    February 2017
  35. ZHEUTLIN AB, Jeffries CD, Perkins DO, Chung Y, et al
    The Role of microRNA Expression in Cortical Development During Conversion to Psychosis.
    Neuropsychopharmacology. 2017 Feb 10. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    January 2017
  36. PEREZ VB, Tarasenko M, Miyakoshi M, Pianka ST, et al
    Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia.
    Neuropsychopharmacology. 2017 Jan 31. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  37. HO NF, Holt DJ, Cheung M, Iglesias JE, et al
    Progressive Decline in Hippocampal CA1 Volume in Individuals at Ultra-High-Risk for Psychosis Who do not Remit: Findings from the Longitudinal Youth at Risk Study.
    Neuropsychopharmacology. 2017 Jan 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    December 2016
  38. PETIT EI, Michalak Z, Cox R, O'Tuathaigh CM, et al
    Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes.
    Neuropsychopharmacology. 2016 Dec 16. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  39. YOUNG JW, Bismark AW, Sun Y, Zhang W, et al
    Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task.
    Neuropsychopharmacology. 2016 Dec 5. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    November 2016
  40. KIM E, Howes OD, Veronese M, Beck K, et al
    Presynaptic Dopamine Capacity in Patients with Treatment Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.
    Neuropsychopharmacology. 2016 Nov 18. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    October 2016
  41. GONG Q, Hu X, Pettersson-Yeo W, Xu X, et al
    Network-Level Dysconnectivity in Drug-Naive First Episode Psychosis: Dissociating Trans-Diagnostic and Diagnosis-Specific Alterations.
    Neuropsychopharmacology. 2016 Oct 26. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    September 2016
  42. MILLER BJ, Goldsmith DR
    Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.
    Neuropsychopharmacology. 2016 Sep 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    August 2016
  43. WIJTENBURG SA, Wright SN, Korenic SA, Gaston FE, et al
    Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL Study.
    Neuropsychopharmacology. 2016 Aug 26. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  44. SCHOONOVER KE, McCollum LA, Roberts RC
    Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.
    Neuropsychopharmacology. 2016 Aug 23. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    July 2016
  45. DE LEEUW M, Bohlken MM, Mandl RC, Hillegers MH, et al
    Changes in White Matter Organization in Adolescent Offspring of Schizophrenia Patients.
    Neuropsychopharmacology. 2016 Jul 21. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    June 2016
  46. HAIG G, Wang D, Othman AA, Zhao J, et al
    The alpha7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
    Neuropsychopharmacology. 2016 Jun 20. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  47. PLITMAN E, Patel R, Chung JK, Pipitone J, et al
    Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.
    Neuropsychopharmacology. 2016 Jun 8. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    May 2016
  48. CHIAPPELLI J, Postolache TT, Kochunov P, Rowland LM, et al
    Tryptophan Metabolism and White Matter Integrity in Schizophrenia.
    Neuropsychopharmacology. 2016 May 4. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    April 2016
  49. ERYILMAZ H, Tanner AS, Ho NF, Nitenson AZ, et al
    Disrupted working Memory Circuitry in Schizophrenia: Disentangling fMRI Markers of Core Pathology Versus other Aspects of Impaired Performance.
    Neuropsychopharmacology. 2016 Apr 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  50. SCHWEHM A, Robinson DG, Gallego JA, Karlsgodt KH, et al
    Age and Sex Effects on White Matter Tracts in Psychosis from Adolescence though Middle Adulthood.
    Neuropsychopharmacology. 2016 Apr 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  51. FRYER SL, Roach BJ, Wiley K, Loewy RL, et al
    Reduced Amplitude of Low-Frequency Brain Oscillations in the Psychosis Risk Syndrome and Early Illness Schizophrenia.
    Neuropsychopharmacology. 2016 Apr 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  52. GOONAWARDENA AV, Heiss J, Glavis-Bloom C, Trube G, et al
    Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism.
    Neuropsychopharmacology. 2016;41:1319-28.
    PubMed     Text format     Abstract available


    March 2016
  53. DU Y, Grace AA
    Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration.
    Neuropsychopharmacology. 2016 Mar 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  54. CASTRO VM, Roberson AM, McCoy TH, Wiste A, et al
    Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study.
    Neuropsychopharmacology. 2016;41:1138-43.
    PubMed     Text format     Abstract available


    February 2016
  55. ENWRIGHT JF, Sanapala S, Foglio A, Berry R, et al
    Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia.
    Neuropsychopharmacology. 2016 Feb 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    January 2016
  56. BALU DT, Li Y, Takagi S, Presti KT, et al
    An mGlu5 Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
    Neuropsychopharmacology. 2016 Jan 7. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  57. WEICKERT CS, Weickert TW
    Hormone modulation improves cognition in schizophrenia.
    Neuropsychopharmacology. 2016;41:384-5.
    PubMed     Text format    


    December 2015
  58. SEGARRA N, Metastasio A, Ziauddeen H, Spencer J, et al
    Abnormal Frontostriatal Activity during Unexpected Reward Receipt in Depression and Schizophrenia: Relationship to Anhedonia.
    Neuropsychopharmacology. 2015 Dec 28. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: